Biotech Values

[dangerM]

> some short-term disruption but no lasting damage

Overall this is correct.

The only exception I could think of: Abbvie reacted more strongly than other pharma companies in the after-hourse trading on the day of the announcement. In a way this makes sense.

If your only lead product's sales depend much on being listed as preferred in many formularies (made possible by kickback payments), then you're a company to fear the end of rebates/safe-harbour protection of kickback payments.